Page last updated: 2024-10-28

hydroxychloroquine and Diabetes, Phosphate

hydroxychloroquine has been researched along with Diabetes, Phosphate in 1 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Research Excerpts

ExcerptRelevanceReference
"This report describes a 32-year-old woman presenting since childhood with progressive calcium pyrophosphate disease (CPPD), characterized by severe arthropathy and chondrocalcinosis involving multiple peripheral joints and intervertebral disks."3.78Novel ANKH amino terminus mutation (Pro5Ser) associated with early-onset calcium pyrophosphate disease with associated phosphaturia. ( Armas, JB; Brown, MA; Couto, AR; Finzel, K; Gruber, BL; Terkeltaub, RA, 2012)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gruber, BL1
Couto, AR1
Armas, JB1
Brown, MA1
Finzel, K1
Terkeltaub, RA1

Other Studies

1 other study available for hydroxychloroquine and Diabetes, Phosphate

ArticleYear
Novel ANKH amino terminus mutation (Pro5Ser) associated with early-onset calcium pyrophosphate disease with associated phosphaturia.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2012, Volume: 18, Issue:4

    Topics: Adult; Antirheumatic Agents; Calcium Pyrophosphate; Chondrocalcinosis; Drug Therapy, Combination; Fe

2012